Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome

Bulent O. Yildiz, Keslie S. Woods, Frank Stanczyk, Al Bartolucci, Ricardo Azziz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Adrenocortical secretion is up-regulated in women with polycystic ovary syndrome (PCOS), and absolute adrenal androgen (AA) excess is evident in -25% of these patients. We hypothesized that AA biosynthesis is an inherited trait and that, as for other inherited traits, AA biosynthesis remains stable over time. To test this hypothesis, we prospectively studied 23 off-treatment PCOS patients and seven age- and body mass index-matched control women on two separate occasions 3-5 yr apart (45.0 ± 19.0 months and 47.4 ± 21.3 months, respectively; P > 0.05). All subjects underwent an acute adrenal stimulation using 0.25 mg ACTH-(1-24), and dehydroepiandrosterone (DHEA), androstenedione, and cortisol (F) were measured 0 and 60 min post ACTH; basal levels of total and free testosterone (T), SHBG, and DHEA sulfate (DHEA-S) were also assessed. Among PCOS patients, the mean DHEA-S levels during the repeat study were significantly lower when compared with the initial assessment (170 ± 107 μg/dl vs. 134 ± 79 μg/dl, respectively; P = 0.02). However, only patients with initial DHEA-S levels above the median (high DHEA-S) experienced a net decrease in the levels of this metabolite (252.5 ± 99.2 μg/dl vs. 174.3 ± 82.5 μg/dl; P = 0.001) over the time of the study; patients with initial DHEA-S levels in the lower half (low DHEA-S) did not experience a change in DHEA-S (94.6 ± 28.8 μg/dl vs. 97.7 ± 56.5 μg/dl; P = 0.85). In patients, the total T levels tended to be higher at the second study, although SHBG levels were also higher, resulting in unchanged free T levels over time. Among controls, no significant changes in basal androgens were observed over the time of the study. There were no significant differences in either the basal or ACTH-stimulated levels of DHEA, androstenedione, or F over the time of the study in either PCOS or control women. We conclude that the adrenocortical secretion of AAs or F in PCOS and control women remains stable over time, supporting the hypothesis that the adrenal response to ACTH may be an inherited trait. Alternatively, a decrease in DHEA-S levels over time was observed but only among PCOS patients whose initial levels of this metabolite were above the group median, suggesting that the activity of sulfotransferase in these patients may be up-regulated by factors other than those affecting adrenocortical biosynthesis and that such regulatory influences attenuate over time.

Original languageEnglish (US)
Pages (from-to)5558-5562
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number11
DOIs
StatePublished - Nov 1 2004

Fingerprint

Dehydroepiandrosterone
Polycystic Ovary Syndrome
Androgens
Time and Motion Studies
Biosynthesis
Adrenocorticotropic Hormone
Androstenedione
Metabolites
Cosyntropin
Sulfotransferases
Dehydroepiandrosterone Sulfate
Hydrocortisone
Testosterone
Body Mass Index

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. / Yildiz, Bulent O.; Woods, Keslie S.; Stanczyk, Frank; Bartolucci, Al; Azziz, Ricardo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 11, 01.11.2004, p. 5558-5562.

Research output: Contribution to journalArticle

Yildiz, Bulent O. ; Woods, Keslie S. ; Stanczyk, Frank ; Bartolucci, Al ; Azziz, Ricardo. / Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 11. pp. 5558-5562.
@article{79721055b1ea4b839136a7db2f0bd78a,
title = "Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome",
abstract = "Adrenocortical secretion is up-regulated in women with polycystic ovary syndrome (PCOS), and absolute adrenal androgen (AA) excess is evident in -25{\%} of these patients. We hypothesized that AA biosynthesis is an inherited trait and that, as for other inherited traits, AA biosynthesis remains stable over time. To test this hypothesis, we prospectively studied 23 off-treatment PCOS patients and seven age- and body mass index-matched control women on two separate occasions 3-5 yr apart (45.0 ± 19.0 months and 47.4 ± 21.3 months, respectively; P > 0.05). All subjects underwent an acute adrenal stimulation using 0.25 mg ACTH-(1-24), and dehydroepiandrosterone (DHEA), androstenedione, and cortisol (F) were measured 0 and 60 min post ACTH; basal levels of total and free testosterone (T), SHBG, and DHEA sulfate (DHEA-S) were also assessed. Among PCOS patients, the mean DHEA-S levels during the repeat study were significantly lower when compared with the initial assessment (170 ± 107 μg/dl vs. 134 ± 79 μg/dl, respectively; P = 0.02). However, only patients with initial DHEA-S levels above the median (high DHEA-S) experienced a net decrease in the levels of this metabolite (252.5 ± 99.2 μg/dl vs. 174.3 ± 82.5 μg/dl; P = 0.001) over the time of the study; patients with initial DHEA-S levels in the lower half (low DHEA-S) did not experience a change in DHEA-S (94.6 ± 28.8 μg/dl vs. 97.7 ± 56.5 μg/dl; P = 0.85). In patients, the total T levels tended to be higher at the second study, although SHBG levels were also higher, resulting in unchanged free T levels over time. Among controls, no significant changes in basal androgens were observed over the time of the study. There were no significant differences in either the basal or ACTH-stimulated levels of DHEA, androstenedione, or F over the time of the study in either PCOS or control women. We conclude that the adrenocortical secretion of AAs or F in PCOS and control women remains stable over time, supporting the hypothesis that the adrenal response to ACTH may be an inherited trait. Alternatively, a decrease in DHEA-S levels over time was observed but only among PCOS patients whose initial levels of this metabolite were above the group median, suggesting that the activity of sulfotransferase in these patients may be up-regulated by factors other than those affecting adrenocortical biosynthesis and that such regulatory influences attenuate over time.",
author = "Yildiz, {Bulent O.} and Woods, {Keslie S.} and Frank Stanczyk and Al Bartolucci and Ricardo Azziz",
year = "2004",
month = "11",
day = "1",
doi = "10.1210/jc.2004-0934",
language = "English (US)",
volume = "89",
pages = "5558--5562",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome

AU - Yildiz, Bulent O.

AU - Woods, Keslie S.

AU - Stanczyk, Frank

AU - Bartolucci, Al

AU - Azziz, Ricardo

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Adrenocortical secretion is up-regulated in women with polycystic ovary syndrome (PCOS), and absolute adrenal androgen (AA) excess is evident in -25% of these patients. We hypothesized that AA biosynthesis is an inherited trait and that, as for other inherited traits, AA biosynthesis remains stable over time. To test this hypothesis, we prospectively studied 23 off-treatment PCOS patients and seven age- and body mass index-matched control women on two separate occasions 3-5 yr apart (45.0 ± 19.0 months and 47.4 ± 21.3 months, respectively; P > 0.05). All subjects underwent an acute adrenal stimulation using 0.25 mg ACTH-(1-24), and dehydroepiandrosterone (DHEA), androstenedione, and cortisol (F) were measured 0 and 60 min post ACTH; basal levels of total and free testosterone (T), SHBG, and DHEA sulfate (DHEA-S) were also assessed. Among PCOS patients, the mean DHEA-S levels during the repeat study were significantly lower when compared with the initial assessment (170 ± 107 μg/dl vs. 134 ± 79 μg/dl, respectively; P = 0.02). However, only patients with initial DHEA-S levels above the median (high DHEA-S) experienced a net decrease in the levels of this metabolite (252.5 ± 99.2 μg/dl vs. 174.3 ± 82.5 μg/dl; P = 0.001) over the time of the study; patients with initial DHEA-S levels in the lower half (low DHEA-S) did not experience a change in DHEA-S (94.6 ± 28.8 μg/dl vs. 97.7 ± 56.5 μg/dl; P = 0.85). In patients, the total T levels tended to be higher at the second study, although SHBG levels were also higher, resulting in unchanged free T levels over time. Among controls, no significant changes in basal androgens were observed over the time of the study. There were no significant differences in either the basal or ACTH-stimulated levels of DHEA, androstenedione, or F over the time of the study in either PCOS or control women. We conclude that the adrenocortical secretion of AAs or F in PCOS and control women remains stable over time, supporting the hypothesis that the adrenal response to ACTH may be an inherited trait. Alternatively, a decrease in DHEA-S levels over time was observed but only among PCOS patients whose initial levels of this metabolite were above the group median, suggesting that the activity of sulfotransferase in these patients may be up-regulated by factors other than those affecting adrenocortical biosynthesis and that such regulatory influences attenuate over time.

AB - Adrenocortical secretion is up-regulated in women with polycystic ovary syndrome (PCOS), and absolute adrenal androgen (AA) excess is evident in -25% of these patients. We hypothesized that AA biosynthesis is an inherited trait and that, as for other inherited traits, AA biosynthesis remains stable over time. To test this hypothesis, we prospectively studied 23 off-treatment PCOS patients and seven age- and body mass index-matched control women on two separate occasions 3-5 yr apart (45.0 ± 19.0 months and 47.4 ± 21.3 months, respectively; P > 0.05). All subjects underwent an acute adrenal stimulation using 0.25 mg ACTH-(1-24), and dehydroepiandrosterone (DHEA), androstenedione, and cortisol (F) were measured 0 and 60 min post ACTH; basal levels of total and free testosterone (T), SHBG, and DHEA sulfate (DHEA-S) were also assessed. Among PCOS patients, the mean DHEA-S levels during the repeat study were significantly lower when compared with the initial assessment (170 ± 107 μg/dl vs. 134 ± 79 μg/dl, respectively; P = 0.02). However, only patients with initial DHEA-S levels above the median (high DHEA-S) experienced a net decrease in the levels of this metabolite (252.5 ± 99.2 μg/dl vs. 174.3 ± 82.5 μg/dl; P = 0.001) over the time of the study; patients with initial DHEA-S levels in the lower half (low DHEA-S) did not experience a change in DHEA-S (94.6 ± 28.8 μg/dl vs. 97.7 ± 56.5 μg/dl; P = 0.85). In patients, the total T levels tended to be higher at the second study, although SHBG levels were also higher, resulting in unchanged free T levels over time. Among controls, no significant changes in basal androgens were observed over the time of the study. There were no significant differences in either the basal or ACTH-stimulated levels of DHEA, androstenedione, or F over the time of the study in either PCOS or control women. We conclude that the adrenocortical secretion of AAs or F in PCOS and control women remains stable over time, supporting the hypothesis that the adrenal response to ACTH may be an inherited trait. Alternatively, a decrease in DHEA-S levels over time was observed but only among PCOS patients whose initial levels of this metabolite were above the group median, suggesting that the activity of sulfotransferase in these patients may be up-regulated by factors other than those affecting adrenocortical biosynthesis and that such regulatory influences attenuate over time.

UR - http://www.scopus.com/inward/record.url?scp=8744222686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744222686&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0934

DO - 10.1210/jc.2004-0934

M3 - Article

VL - 89

SP - 5558

EP - 5562

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -